Evommune (EVMN) Return on Assets (2025 - 2026)

Evommune's (EVMN) quarterly Return on Assets came in at 0.01% in Q1 2026, down 20.96% on a QoQ basis from 0.01% in Q4 2025.

Evommune (EVMN) Return on Assets (2025 - 2026) Analysis & Trends

Evommune (EVMN) has 2 years of Return on Assets data on file, last reported at 0.01% in Q1 2026.

On a quarterly basis, Return on Assets changed N/A year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a N/A change from a year earlier, with the FY2025 full-year figure at 0.01%, changed N/A from the prior year.
Return on Assets for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
Over the last five years, Return on Assets for EVMN reached as high as 0.01% in Q4 2025 and fell as low as 0.01% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-0.69%
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-0.01%
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.00%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-0.80%
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	0.00%
10	Evommune	381.48 Mn	170.02 Mn	-	-0.01%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-0.01%
Dec 31, 2025	-0.01%